Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

Author(s):
Furst, D.E.; Keystone, E.C.; Braun, J.; Breedveld, F.C.; Burmester, G.R.; Benedetti, F. de; Dorner, T.; Emery, P.; Fleischmann, R.; Gibofsky, A.; Kalden, J.R.; Kavanaugh, A.; Kirkham, B.; Mease, P.; Sieper, J.; Singer, N.G.; Smolen, J.S.; Riel, P.L.C.M. van; Weisman, M.H.; Winthrop, K.
Published
2010
Publication type
Article / Letter to editor
tumor-necrosis-factor systemic-lupus-erythematosus b-cell depletion placebo-controlled trial interleukin-1 receptor antagonist alpha monoclonal-antibody modifying antirheumatic drugs juvenile idiopathic arthritis randomized controlled-trials onset stills-disease
Date issued
2010-01-31
Language
English
Is part of
Annals of the Rheumatic Diseases (2010), Vol. 69, p. 2-29
hdl
1887/108571